Therapy of acute vulvovaginal candidiasis, vaginal microbiocenosis

Therapy of acute vulvovaginal candidiasis, vaginal microbiocenosis
Candidal vulvovaginitis (CVV) is one of the most common infectious diseases affecting the vulvar and vaginal mucosa, caused by yeast-like fungi of the genus Candida.
Author: P.N. Krotin, O.V. Kirilenko
St. Petersburg State Budgetary Healthcare Institution "Youth Center" (GC DC "Yuventa"), St. Petersburg, Russia
Keywords: #CandidalVulvovaginitis, #VaginalMicrobiocenosis, #Lactobacilli, #Ecofucin®

The incidence of CVV has nearly doubled over the past 10 years and currently accounts for 30–45% of all infectious diseases affecting the vulva and vagina. According to researchers, 70–75% of women experience at least one episode of CVV in their lifetime, and in 5–10% of cases, the disease becomes recurrent [1–4]. Alongside clinically manifest disease (acute, chronic, or recurrent CVV), there is also asymptomatic vaginal colonization by yeast-like fungi [4].



Summary

Objective: To evaluate the efficacy and safety of the drug Ecofucin® (intravaginal suppositories) based on the time to achieve clinical and microbiological remission in patients with acute candidal vaginitis/vulvovaginitis.

Materials and methods: The study included female patients aged 18 to 45 years with acute candidal vaginitis/vulvovaginitis. They were divided into two groups: the main group (36 patients) received Ecofucin® intravaginally (natamycin 100 mg with lactulose 300 mg); the control group (36 patients) received Pimafucin® suppositories (natamycin 100 mg) once daily for 6 days. The efficacy and safety of the study drugs were assessed based on examination results, laboratory tests, and patient diary entries. Follow-up visits were conducted on days 4, 7, and 37 (±2) from the start of treatment (or on day 30 (±2) after the end of therapy).

Results: The combination of the antifungal drug natamycin and a prebiotic in the intravaginal suppositories promotes faster achievement of clinical remission and complete elimination of the CVV pathogen, leading to intensive growth of lactobacilli, which are the main competitors of yeast-like fungi in the vaginal microbiocenosis. The study demonstrated good tolerability of Ecofucin by the patients, and no side effects were recorded during the study.

Keywords: candidal vulvovaginitis, vaginal microbiocenosis, lactobacilli.

For citation: Krotin P.N., Kirilenko O.V. Combination of an antifungal drug and a prebiotic in the therapy of acute candidal vulvovaginitis. RMJ. Mat' i ditya [Mother and Child]. 2019;2(*):1–7.

Комбинация противогрибкового препарата и пребиотикав терапии острого кандидозного вульвовагинита

Our Products:

Over-the-Counter (OTC):

Lactofiltrum® 325 mg + 120 mg , Filtrum® 400 mg , Micrasim® 25,000 IU , Micrasim® 10,000 IU , Micrasim® 40,000 IU , Ecofuril® capsules 100 mg Ecofuril® capsules 200 mg , Ecofuril® oral suspension 90 ml , Ecofucin® vaginal suppositories 100 mg , Ecobiotic Immuno , Lactofiltrum® Skin detox , Heli-Stop® tablets 120 mg , Vikalin tablets , Potassium Orotate tablets 500 mg , Lactulose syrup , Pancreatin tablets 100 mg , Simeotic® 40 mg , Simeotic® 80 mg

Prescription-Only:

Minolexin® capsules 50 mg , Minolexin® capsules 100 mg , Azithromycin Ecomed® tablets 250 mg , Azithromycin Ecomed® powder for oral suspension 100 mg/5 ml vial , Azithromycin Ecomed® powder for oral suspension 200 mg/5 ml vial , Azithromycin Ecomed® tablets 500 mg , Amoxicillin Ecobol® tablets 250 mg , Amoxicillin Ecobol® tablets 500 mg , Ecoclav® (Amoxicillin + Clavulanic Acid) powder for oral suspension 125 mg+31.25 mg/5 ml , Ecoclav® (Amoxicillin + Clavulanic Acid) powder for oral suspension 250 mg+62.5 mg/5 ml , Ecoclav® (Amoxicillin + Clavulanic Acid) tablets 250 mg+125 mg , Ecoclav® (Amoxicillin + Clavulanic Acid) tablets 500 mg+125 mg , Ecoclav® (Amoxicillin + Clavulanic Acid) tablets 875 mg+125 mg , Ciprofloxacin Ecocifol® tablets 500 mg , Ciprofloxacin Ecocifol® tablets 250 mg , Clarithromycin Ecozitrin® tablets 250 mg , Clarithromycin Ecozitrin® tablets 500 mg , Levofloxacin Ecolevid® tablets 500 mg , Levofloxacin Ecolevid® tablets 250 mg , Levofloxacin Ecolevid® tablets 250 mg , Gelmindazole tablets 100 mg , Itraconazole capsules 100 mg , Motonium® tablets 10 mg , Nimesulide tablets 100 mg , Nimesulide® granules for oral suspension , Ursoliv® capsules 250 mg , Amoxicillin tablets 250 mg , Amoxicillin tablets 500 mg , Amiodarone tablets 200 mg , Verapamil tablets 80 mg , Diazolin 50 mg , Diazolin 100 mg , Indapamide tablets 2.5 mg , Captopril-STI tablets 50 mg , Methionine tablets 250 mg , Nicergoline tablets 10 mg , Omeprazole capsules 20 mg , Simvastatin tablets 20 mg , Simvastatin tablets 10 mg , Simvastatin tablets 40 mg , Erythromycin tablets 250 mg